24/7 Patient Assistance: 760-405-8205

Scott J. Antonia, MD,PhD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer

specialties & services

  • Bio & Insurance Information

    Dr. Scott Antonia graduated the medical school from University of Connecticut School of Medicine and completed both his internship and fellowship program at Yale New Haven Hospital. He is specialized and board certified in medical oncology and has been practicing medicine for more than 20 years. Dr. Antonia is affiliated with Moffitt Cancer Center and during his career, he has also published several writings of medical interest in collaboration with other doctors.

  • Education & Training


    University Of Connecticut School Of Medicine Graduated in 1989

    Medical School


    Yale New Haven Hospital Completed in 1990



    Yale New Haven Hospital Completed in 1991



    Yale University School Of Med Completed in 1994


  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Moffitt Cancer Center

    Languages: English/Spanish

    (888) 663-3488

    12902 USF Magnolia Drive

    Tampa, Florida 33612

    Read More

    Tampa General Hospital

    Languages: English/Spanish

    (813) 844-7000

    1 Tampa General Cir

    Tampa, Florida 33606

    Read More
  • Publications & Memberships

    Dr. Scott J. Antonia has contributed to 3 publications.

    Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

    Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA Lancet Oncol. 2016 Mar;17(3):299-308.

    See more >>

    The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.

    Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ BMC Cancer. 2016 Mar;16(1):176.

    See more >>

    Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

    Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD J Clin Oncol. 2016 Jun

    See more >>